Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Going Short who wrote (8001)	6/29/1999 10:59:00 AM
From: John F. Dowd	Read Replies (1) \| Respond to of 9523

Don't hang by your thumbs while waiting their pipeline is loaded with new products. Here is one for instance: PFE is big into genomes as well and has 1000's of other products just beginning trials of one sort or another. The only thing that will slow PFE down (along with others) is if drugs are included in outpatient Medicare. The next step will be government intervention in pricing. JFD June 29, 1999 06:24 Inhale Reports Start of Phase III Trial Patient Dosing for Inhaleable Insulin SAN CARLOS, Calif.--(BW HealthWire)--June 29, 1999--Inhale Therapeutic Systems, Inc. (Nasdaq:INHL) today reported that the first patients have begun dosing for the Phase III clinical trial for inhaleable insulin. The clinical trial is being managed by Inhale's collaborator Pfizer Inc.(NYSE:PFE) to test the systemic delivery of insulin through the lungs using Inhale's pulmonary delivery system. The Phase III clinical program will consist of several protocols for type 1 and type 2 diabetics and is expected to involve more than 117 sites. "The start of Phase III dosing is a major milestone for Inhale. The Phase IIb clinical trial, which involved approximately 190 out-patients, was the largest test ever conducted for systemic delivery of a protein through the lung. We look forward to data from an expanded patient population," said Robert Chess, Chairman and co-CEO of Inhale. Diabetes is a widespread and chronic condition which results when the body produces either no insulin or inadequate amounts to metabolize sugars normally. The disease affects more than 142 million people worldwide, and the number of cases is expected to double by the year 2025, according to the World Health Organization. Unless properly treated, diabetes can result in serious medical complications which include kidney failure, blindness, and cardiovascular and neurological conditions. The American Diabetes Association estimates the combined direct and indirect cost of the disease is $98 billion in the U.S. alone. Use of insulin can play an important role in the management of diabetes. Currently insulin can be delivered only by injection. It is estimated that more than 50 million people worldwide now use injectable insulin. Inhale, Pfizer, and Pfizer's collaborator Hoechst Marion Roussel are developing a pulmonary delivery system for insulin to address the need for a convenient, non-injectable delivery system. Inhale's pulmonary delivery system administers fine aerosol powders to the deep lung. From the deep lung, the aerosolized insulin is transported through the lung tissue to the bloodstream for systemic distribution. Inhale, located in San Carlos, Calif., is developing pulmonary delivery systems to create a range of inhaleable drugs, including peptides and proteins, for systemic and local lung indications. The company has tested six drugs in human clinical trials using its delivery system and has feasibility and development partnerships with several pharmaceutical and biotechnology companies, including Biogen, Centeon, Lilly, and Pfizer. This release contains forward-looking statements that reflect management's current views as to the company's collaborative arrangements, clinical trials, product developments, manufacturing scale-up, and other future events and operations. These forward-looking statements involve uncertainties and other risks that are detailed in Inhaler's reports and other filings with the SEC, including its Form 10-K for the year ending Dec. 31, 1998. Actual results could differ materially from these forward-looking statements. CONTACT: Inhale Therapeutic Systems, Inc. Joyce Strand, 650/631-3138 INHALE THERAPEUTIC SYSTEMS - INHL Price 24 7/8 Net Change +1 13/16 Volume (000) 118 Day High 25 Day Low 23 5/16 PFIZER INC - PFE Price 101 7/16 Net Change +3/8 Volume (000) 690 Day High 101 13/16 Day Low 101 1/8 as of 06/29/99 10:50 AM EDT Only $9.99 per trade. More Info INHL PFE